UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results February 25, 2019 at 4:05 PM EST PDF Version SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report financial results for the fourth quarter and full year ended December 31, 2018, on Wednesday, March 6, 2019, after Nasdaq market close. UNITY will not conduct a conference call in conjunction with the financial results press release. About UNITY UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter. Media Austine GraffUNITY Biotechnology 707-593-6151 email@example.com Source: Unity Biotechnology, Inc.